Advertisement

Supply Chain

The Food and Drug Administration recently rejected Dynavax Technology Corp.'s hepatitis B drug, Heplisav-B, for the second time in three years, reports Reuters.

Advertisement

The Food and Drug Administration recently approved Vemlidy, a once-daily treatment for patients with compensated liver disease caused by chronic hepatitis B virus.

As the healthcare industry moves from a fee-for-service model to value-based care, controlling spend on high-value supplies is more critical than ever. The use of automation and data analytics allows supply chain leaders to transform data into actionable insights that…

Advertisement